QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer

Summary

Primary End Point: \- To compare the overall survival (OS) using QYHJ Granules or Xeloda as the second therapy in patients with metastatic pancreatic cancer. Secondary End Points: * Compare clinical efficacy by other measures including PFS,tumor response,and changes in quality of life (QOL) between these two groups. * Examine the feasibility and assess the side effects of treatment using QYHJ Granules in patients with metastatic pancreatic cancer.

Timeline

Start

2013-01

Primary completion

2015-08

Completion

2015-12

Drugs

Indications